ABSTRACT
Recent data from Denmark and Europe (Olesen and Leonardi 2003; Olesen et al. 2008) indicate that brain disorders account for 12% of all direct costs in the Danish health system and that 9% of the total drug consumption was used for treatment of brain diseases. Expenses for brain diseases constituted 3% of the country’s gross national product, and the total expenses for all investigated
17.1 Introduction .......................................................................................................................... 341 17.2 General Aspects of NO ......................................................................................................... 342
17.2.1 NO Synthase Enzymes ............................................................................................. 342 17.2.2 Synthesis of NO ........................................................................................................344 17.2.3 Localization of NOS in Central Nervous System .....................................................344 17.2.4 Regulation of NOS Activity ...................................................................................... 345 17.2.5 Targets of NO ............................................................................................................ 345
17.3 NO and Depression ...............................................................................................................346 17.3.1 Preclinical Studies ....................................................................................................346
